Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage ...

Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A. The HAVEN 7 trial showed that emicizumab is both safe and effective ...

Novo Nordisk and Shire are well established in the haemophilia market, worth around $11 billion a year, and Roche is hoping to make some serious inroads with emicizumab. Analysts Evaluate Pharma ...